Gritstone bio, Inc.

Gritstone bio — Gritstone Oncology — Corporate Update (July 2020)

51 slides from Gritstone bio's corporate update, Jul 13, 2020

  1. Slide 1: Clinical Data Update & Near-term Phase 2 Plans

    Exhibit 99.1 Clinical Data Update & Near-term Phase 2 Plans 13 July 2020 1Exhibit 99.1 Clinical Data Update & Near-term Phase 2 Plans 13 July 2020 1

  2. Slide 2: Safe Harbor and Forward-Looking Statements

    Safe Harbor and Forward-Looking Statements This presentation contains forward-looking statements including, but not limited to, statements related to our preclinical and clinical product candidates, GRANITE, SLATE, and our bispecific antibody program. All statements other than statements of historic

  3. Slide 3: Agenda

    • Gritstone’s GRANITE and SLATE product candidates - Dr Andrew Allen • Phase 1 Clinical Trial Data - Dr Daniel Catenacci • Phase 2 Studies in Advanced Disease - Dr Andrew Allen - GRANITE – advanced CRC & gastric cancer - SLATE - post-CPI advanced NSCLC • Company Milestones - Dr Andrew Allen • Q&A -

  4. Slide 4: Gritstone Is Steadily Delivering Data to Validate the Platform

    Gritstone Is Steadily Delivering Data to Validate the Platform 2021 2022 MID-2020 EFFICACY: • Large single-arm cohorts ESMO-IO • Randomized trial data EARLY EFFICACY: DEC 2019 • Strong signals (MSS Nat Biotech colorectal cancer) • Signals (Gastric cancer, 2018 IMMUNOGENICITY: NSCLC, Urothelial SITC

  5. Slide 5: Gritstone's Approach: Next Generation Cancer Immunotherapy Demands Excellence in Two Key Dimensions

    Gritstone’s Approach: Next Generation Cancer Immunotherapy Demands Excellence in Two Key Dimensions Target Product Profile T Cells Neoantigen Identification 5 5 Potent Platform for T Cell GenerationGritstone’s Approach: Next Generation Cancer Immunotherapy Demands Excellence in Two Key Dimensions Ta

  6. Slide 6: Gritstone's EDGE Leads The Field in Neoantigen Identification

    TM Gritstone’s EDGE Leads The Field in Neoantigen Identification Bulik-Sullivan, et. al. December 2018 EDGE is a neural network model of HLA peptide presentation 6 6TM Gritstone’s EDGE Leads The Field in Neoantigen Identification Bulik-Sullivan, et. al. December 2018 EDGE is a neural network model o

  7. Slide 7: Gritstone Has Developed a Unique, Potent Platform for Delivering Antigens

    Gritstone Has Developed a Unique, Potent Platform for Delivering Antigens to the Immune System to Drive a Strong T Cell Response Non-Human Primate Experiment: 6 SIV antigens Heterologous Prime/Boost ChAdV + SAM + anti-CTLA-4 Boost Memory Cells Prime Up to 8% of peripheral CD8+ T cells are antigen- s

  8. Slide 8: Personalized Immunotherapy - GRANITE

    Many Solid Tumor Patients Will Have Their Own Unique Neoantigens Enabling Personalized Immunotherapy - GRANITE Personalized GRANITE 3. 5. 1. 2. 4. Neoantigen Simple Routine Personalized Sequencing Prediction Injection Biopsy Immunotherapy Immunotherapy Routine clinical biopsy Tumor DNA Gritstone EDG

  9. Slide 9: SLATE Delivers Shared Neoantigens - Off-the-Shelf Therapy

    SLATE Delivers Shared Neoantigens To Selected Patients Using Gritstone’s Prime/Boost Platform – Off-the-Shelf Therapy Boost Prime ChAdV Vector SAM Vector SLATE Shared Neoantigen Cassette • “Off-the-shelf” Neoantigen Immunotherapy • 20 cancer driver mutations • Efficient patient selection via gene pa

  10. Slide 10: Efficacy of Neoantigen Immunotherapy: How Will it Manifest?

    Efficacy of Neoantigen Immunotherapy: How Will it Manifest? Form of response to neoantigen immunotherapy likely different vs CPI alone where intra-tumoral T cells already present 4 Trafficking of T cells to tumors (CTLs) 3 5 Priming and activation Infiltration of T Blood Vessel (APCs & T cells into

  11. Slide 11: Phase One Clinical Trial Data

    PHASE ONE CLINICAL TRIAL DATA Dr Dan Catenacci Director GI Oncology Program Assistant Director of Translational Research Comprehensive Cancer Center University of Chicago 11PHASE ONE CLINICAL TRIAL DATA Dr Dan Catenacci Director GI Oncology Program Assistant Director of Translational Research Compre

  12. Slide 12: GRANITE and SLATE Phase One Studies Are Very Similar

    GRANITE and SLATE Phase One Studies Are Very Similar GRANITE SLATE PHASE 1 SLATE personalized off-the-shelf Objectives: • Safety and RP2D off-the-shelf • Immunogenicity Dose Level 4 Dose High Frequency KRAS Mutation Level 3 Dose High Frequency • Lung Level 2 KRAS Mutation • Pancreatic Dose • Colorec

  13. Slide 13: Treatment of Previously Treated Metastatic Patients

    GRANITE and SLATE: Treatment of Previously Treated Metastatic Patients GRANITE SLATE (n=10) (n=19) Age (mean, range) 59 (38-76) 58 (33-83) Gender (Female/Male) 4/6 12/7 # of doses ChAdV 11 19 SAM 44 39 Nivolumab (IV) 61 58 Ipilimumab (SC) 14 47 Tumor Types NSCLC 1 6 Microsatellite stable (MSS)-CRC 5

  14. Slide 14: GRANITE Therapy is Well Tolerated

    GRANITE Therapy is Well Tolerated with TRAEs Indicative of an Immune Response to the Vaccine No DLTs; TRAEs all Grade 1/2 with exception of Grade 3 Hyperthyroidism in 1 patient and self-limiting, asymptomatic Grade 3 CK elevation in 1 patient Treatment-related adverse events (TRAEs) after ChAdV or S

  15. Slide 15: Fever is the Only SAE Associated with GRANITE

    Fever is the Only SAE Associated with GRANITE Neoantigen Vaccination All serious adverse events (SAEs) after ChAdV or SAM Safety n = 10 (all patients treated with concurrent nivolumab) 12 ChAdV (1x10 vp) SAM 100 ug 300 ug a No SC IPI With SC IPI 30 ug 100 ug + SC IPI + SC IPI (n=5) (n=5) (n=3) (n=2)

  16. Slide 16: SLATE Therapy is Well Tolerated

    SLATE Therapy is Well Tolerated with TRAEs Indicative of an Immune Response to the Vaccine Treatment-related adverse events (TRAEs) after ChAdV or SAM • All grade 1/2 with exception of: Safety n = 19 (all patients treated with concurrent nivolumab) 12 ChAdV (1x10 vp) SAM o one patient with grade 3 f

  17. Slide 17: SLATE SAEs: Mostly Attributable to CPI

    SLATE SAEs: Mostly attributable to CPI, no other clear pattern All serious adverse events (SAEs) after ChAdV or SAM Safety n = 19 (all patients treated with concurrent nivolumab) 12 ChAdV (1x10 vp) SAM 30 ug 100 ug 300 ug No SC ipi With SC ipi 30 ug + SC IPI + SC IPI + SC IPI (n=2) (n=17) (n=2) f (n

  18. Slide 18: GRANITE

    GRANITE 18GRANITE 18

  19. Slide 19: Strong Neoantigen-specific CD8+ T Cell Responses Across All Patients

    Strong Neoantigen-specific CD8+ T Cell Responses Consistently Induced Across All Patients (Ex Vivo ELISpot Assay with Short Peptides) G1 G2 G3 G4 G6 G7 G8 * * Poor cellular recovery 19 19 G5: Data not available due to lack of samples LOD = limit of detectionStrong Neoantigen-specific CD8+ T Cell Res

  20. Slide 20: Each Patient Has CD8+ T Cell Responses To Multiple Neoantigens

    Each Patient Has CD8+ T Cell Responses To Multiple Neoantigens Mini-pools of multiple short neoantigenic peptides (a mini-pool Patient G2 (leukapheresis): 12 of 20 + is a subset of the 20 in the vaccine) studied in each patient with neoantigens elicit CD8 T-cell responses sufficient PBMCs 20 20 G6:

  21. Slide 21: Do Therapy-Induced Neoantigen-Specific T Cells Traffic to the Tumor?

    Do Therapy-Induced Neoantigen-Specific T Cells Traffic to the Tumor? T Cell Receptor (TCR) Sequence Analysis Can Address This RNA sequencing of TCRβ of Neoantigen-reactive CD8+ T cells Screen Week 12 T cells expanding in blood Blood 10x Genomics Week 1 4 8 12 16 Can neoantigen reactive T cells expan

  22. Slide 22: G3: Joint Expansion of Neoantigen Reactive CD8 T cells in Blood and Tumor

    G3: Joint Expansion of Neoantigen Reactive CD8 T cells in the Blood and Tumor On Treatment Indicates Vaccine Driven Tumor T cell Infiltration 27 TCR���� s were expanded on-treatment in neoantigen-peptide- 40 TCR���� s significantly expanded in the on-treatment stimulated PBMCs, 5 of which infiltrate

  23. Slide 23: GRANITE: No DLTs and frequent treatment beyond apparent radiologic progression

    GRANITE: No DLTs and frequent treatment beyond apparent radiologic progression GRANITE chemotherapy G1 6 RPD 15 GEA chemotherapy + Dose Level 1 anti-PD-(L)1 G2 3 5 (NED) 12 ChAdV GEA surgery +SAM: 30 µg G3 RPD 6 5 9 + nivolumab NSCLC radiation G4 15 2 ChAdV/SAM/nivolumab Dose Level 2 MSS-CRC G5 ChAd

  24. Slide 24: G2 (DL1): Prolonged disease-free period on therapy after surgery

    G2 G2 (DL1): Prolonged disease-free period on therapy after surgery Study Treatment Every 4 weeks over first 6 months, then every 3 months x 2 Prior Therapy Weeks 0 4 36 52 8 20 12 16 24 FOLFOXIRI FOLFOXIRI Nivolumab Surgery (2 months) (2 months) 59-year old male with metastatic gastric cancer Ex vi

  25. Slide 25: G3 (DL1): NSCLC Patient with Progression on Prior CPI

    G3 G3 (DL1): NSCLC Patient with Progression on Prior CPI – Evidence of Tumor Control (Clinical Benefit, ctDNA Control) Until T Cell Decline Study Treatment Prior Therapy Every 4 weeks over first 6 months, then 3-month interval carboplatin chemoradiation PD SD 4 0 Weeks 36 + gemcitabine + durvalumab

  26. Slide 26: G3 (DL1): Slow Expansion of Lung Nodules on CT Imaging

    G3 G3 (DL1): Slow Expansion of Lung Nodules on CT Imaging with Cavitation and No New Lesions Week 24 Week 8 Week 16 (+53% relative (+34% relative (+37% relative Baseline to baseline) to baseline) to baseline) 26 26G3 G3 (DL1): Slow Expansion of Lung Nodules on CT Imaging with Cavitation and No New L

  27. Slide 27: ctDNA May Help Understand Tumor Biology when CT Scans Uninformative

    ctDNA May Help Understand Tumor Biology when CT Scans Uninformative Advanced melanoma patients treated with CPI can show pseudoprogression – ctDNA changes may identify these patients 1 1 29 Patients with metastatic melanoma treated with anti-PD1 who progressed on first scan 18 11 In patients with pr

  28. Slide 28: G8 (DL3): Clear Evidence of Clinical Benefit in MSS-CRC Patient

    G8 G8 (DL3): Clear Evidence of Clinical Benefit in MSS-CRC Patient Study Treatment Prior Therapy Every 4 weeks over first 6 months FOLFOX/bev FOLFIRI/bev PD 0 20 Weeks 4 50-year old female with (15 months) (6 months) Nivo MSS-CRC Ipi 5-FU/bev Clinical status • 112+ days on study, clinically feeling

  29. Slide 29: G8 (DL3): Lung CT Shows Transient Lesion Expansion (Slide 1 of 2)

    G8 G8 (DL3): Lung CT Shows Transient Lesion Expansion at Week 8 (T Cell Infiltration?) then Contraction (Slide 1 of 2) Baseline Week 8 Week 16 Multiple lung lesions increasing in size at 8 weeks and shrinking at 16 weeks below baseline 29 29G8 G8 (DL3): Lung CT Shows Transient Lesion Expansion at We

  30. Slide 30: G8 (DL3): Lung CT Shows Transient Lesion Expansion (Slide 2 of 2)

    G8 G8 (DL3): Lung CT Shows Transient Lesion Expansion at Week 8 (T Cell Infiltration?) then Contraction (Slide 2 of 2) Baseline Week 8 Week 16 Multiple lung lesions increasing in size at 8 weeks and shrinking at 16 weeks below baseline 30 30G8 G8 (DL3): Lung CT Shows Transient Lesion Expansion at We

  31. Slide 31: G8 (DL3): Large Liver Lesion Unchanged in Size

    G8 G8 (DL3): Large Liver Lesion Unchanged in Size (but LFTs Normalized) Baseline Week 8 Week 16 Mixed response of two target liver lesions with one stable and one decreasing in size 31 31G8 G8 (DL3): Large Liver Lesion Unchanged in Size (but LFTs Normalized) Baseline Week 8 Week 16 Mixed response of

  32. Slide 32: GRANITE Conclusions to Date

    GRANITE Conclusions to Date • Data to dose level 3 show good tolerability - Vaccine elicits transient fever and injection site reaction as expected - Customary CPI-induced immune-related adverse events • Strong, consistent induction of killer CD8+ T cells, specific to multiple neoantigens, which hav

  33. Slide 33: SLATE

    SLATE 33SLATE 33

  34. Slide 34: SLATE: CD8+ T Cells Induced Against Multiple KRAS Driver Mutations

    SLATE: CD8+ T Cells Consistently Induced Against Multiple KRAS Driver Mutations but ex vivo ELISpot Positive in Subset of Patients Only SLATE drives detectable CD8+ T cell responses against single neoantigens S2 KRAS G12C Ex vivo ELISpot CD8+ T cell responses against single neoantigens from multiple

  35. Slide 35: SLATE: TP53 Neoantigens Seem Immunodominant

    mut SLATE: TP53 Neoantigens Seem Immunodominant – Although Rarer mut than KRAS Neoantigens, they Drive Strong CD8+ T Cell Responses Responses to 3/3 TP53 mutations tested to date; mutations presented by 3 different Class I HLA alleles Ex vivo ELISpot Ex vivo ELISpot Ex vivo ELISpot S2 S3 S9 Ex vivo

  36. Slide 36: SLATE: NSCLC Patients Have Largest Degree of Clinical Benefit

    SLATE: Patients with NSCLC (All of Whom Progressed on Prior IO) Have Largest Degree of Clinical Benefit S1 S2 S3 NSCLC S6 S10 S14 S4 S7 S12 MSS-CRC S13 S17 S18 S5 S9 PDA S11 S16 S19 S8 Ovarian S15 Ampullary adeno 0 5 10 15 20 25 30 35 Weeks after Prime Patient remaining on study treatment Dose Level

  37. Slide 37: S2 (DL1): Good Clinical Response with ctDNA Reduction

    S2 S2 (DL1): Good Clinical Response to Therapy with ctDNA Reduction and Minor Tumor Shrinkage on CT Scan Every 4 weeks over first 6 months Prior Therapy Weeks 0 4 24 Carboplatin/pemetrexed/ Pembrolizumab Anti-TIGIT 84-year old female PD Nivolumab (4 months, SBRT (2 months) (10 months, with NSCLC; BO

  38. Slide 38: S2 (DL1): Increased Immune Infiltration in Post Treatment Biopsy

    S2 S2 (DL1): Increased Immune Infiltration, Including CD8+ T Cells, Observed in Post Treatment Biopsy Baseline Full panel analysis On treatment CD4 PD-L1 CD8a CD68 CD45RO Pan-Cytokeratin Granzyme B DAPI FoxP3 38 38S2 S2 (DL1): Increased Immune Infiltration, Including CD8+ T Cells, Observed in Post T

  39. Slide 39: S2 (DL1): Minor Tumor Shrinkage on CT Scan

    S2 S2 (DL1): Good Clinical Response to Therapy with ctDNA Reduction and Minor Tumor Shrinkage on CT Scan Baseline Week 8 Week 16 Week 24 77 mm* 75 mm* 89 mm* 95 mm* (-19% relative to (-21% relative to (-6% relative to baseline) baseline) baseline) 39 39 *Sum of longest diameters of two target lesion

  40. Slide 40: S3 (DL2): Sustained Clinical Benefit after Progression on Pembrolizumab-Chemotherapy

    S3 S3 (DL2): Sustained Clinical Benefit in Patient after Progression on Front-Line Pembrolizumab-Chemotherapy Prior Therapy Every 4 weeks over first 6 months Pembrolizumab + 55-year old male Weeks 0 4 PD 28 Carboplatin/pemetrexed with NSCLC; (8 months, BOR = PD) Nivolumab KRAS G12C Ipilimumab IVS EL

  41. Slide 41: SLATE Conclusions to Date

    SLATE Conclusions to Date • Data to dose level 4 show good SLATE tolerability with expected CPI-induced immune-related adverse events • RP2D at highest evaluated dose in Phase 1 (dose level 4) • Strong, consistent induction of CD8+ T cells to some neoantigens (TP53 mutations) which display features

  42. Slide 42: Phase Two Studies in Advanced Disease

    PHASE TWO STUDIES IN ADVANCED DISEASE Dr Andrew Allen 42PHASE TWO STUDIES IN ADVANCED DISEASE Dr Andrew Allen 42

  43. Slide 43: GRANITE Phase 2 Begins 2H20

    GRANITE Phase 2 Begins 2H20: Pursue Colorectal Cancer Signal & Continue to Study Gastric Cancer Strong Efficacy Signal with Single-Arm Trial if Multiple Responses Observed in MSS-CRC Phase 1 Single-Arm Phase 2 Cohorts in Patients with Advanced Tumors DL4 MSS-CRC Post FOLFOX/FOLFIRI Single-arm trial;

  44. Slide 44: SLATE Phase 2 Begins 2H20 With Focus on Post-IO NSCLC

    SLATE Phase 2 Begins 2H20 With Focus on Post-IO NSCLC mut mut Pursue signals observed in dose escalation (KRAS & TP53 ) and optimize epitope cassette Phase 1 Single-Arm Phase 2 Cohorts in Patients with Advanced Tumors Neoantigen Cassette v1 N= ~10 patients DL4 2H2020 P53 mutation+ tumors • Ovarian C

  45. Slide 45: SLATE Optimization: Repeating Epitopes Within the Antigen Cassette

    SLATE Optimization: Repeating Epitopes Within the Vaccine Antigen Cassette Strongly Increases Antigen-Specific T-cell Response Key issues are epitope competition and epitope immunodominance 1 2 3 4 5 6 7 gp100 9 10 11 12 13 14 15 16 17 18 Trp2 20 1x: 4x: gp100 2 Trp2 4 5 gp100 2 Trp2 4 5 gp100 2 Trp

  46. Slide 46: Future Step: Assess Adjuvant Immunotherapy in Stage II/III NSCLC

    Future Step: Assess Adjuvant Immunotherapy in Stage II/III NSCLC Adjuvant** Stage III*** Neoadjuvant* PACIFIC trial of durvalumab maintenance after Overall survival in NSCLC patients by disease stage at diagnosis chemoradiation for unresectable Stage III NSCLC IA IB IIA IIB IIIA Neoadjuvant nivoluma

  47. Slide 47: Conclusions & Company Milestones

    CONCLUSIONS & COMPANY MILESTONES Dr Andrew Allen 47CONCLUSIONS & COMPANY MILESTONES Dr Andrew Allen 47

  48. Slide 48: GRANITE & SLATE Immunotherapy

    GRANITE & SLATE IMMUNOTHERAPY Demonstrating clear signals of efficacy – now driving into phase 2 trials to establish path to registration • Phase 1 trials with intensive translational medicine elements generating substantial insights – series of “N of 1” clinical trials informing program development

  49. Slide 49: GRTS: Sequential Data Readouts Over Next Months

    GRTS: Sequential Data Readouts Over Next 18 Months Anticipated Milestones 2H20 1H21 2H21 1H22 GRANITE Phase 1 Dose Level 4 Data Bispecific Antibody DC Nomination mut mut SLATE Phase 2 TP53 & KRAS Cassette 1 Data GRANITE Phase 2 MSS-CRC Data GRANITE Phase 2 Gastric Cancer Data SLATE Phase 2 Post-IO N

  50. Slide 50: Acknowledgements

    Acknowledgements • Patients and their families • GRANITE and SLATE Investigators, research nurses, study coordinators, and site staff • Gritstone Oncology staff supporting the study • Bristol-Myers Squibb for supply of nivolumab and ipilimumab 50 50Acknowledgements • Patients and their families • GR

  51. Slide 51: Thank You

    Thank You 51Thank You 51

Gritstone Oncology — Corporate Update (July 2020) on 6ix